MedPath

Comparison of serum levels of cobalamine after giving a thrice weekly dose versus once weekly dose of methylcobalamin in patients suffering from peripheral neuropathy

Phase 4
Conditions
Health Condition 1: null- Peripheral neuropathy
Registration Number
CTRI/2017/02/007804
Lead Sponsor
Wockhardt limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
34
Inclusion Criteria

•Age > 18 years

•Subjects diagnosed with peripheral neuropathy through nerve conduction velocity test or healthy volunteers

•Ability to give written informed consent

Exclusion Criteria

•Females who are pregnant or lactating

•History of clinically significant metabolic, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological or psychiatric disorders

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum Cobalmine levels after multiple and single dose of trial medicationsTimepoint: baseline <br/ ><br>Day 8 <br/ ><br>Day 15
Secondary Outcome Measures
NameTimeMethod
adverse eventsTimepoint: at all visits;serum Homocysteine levelsTimepoint: baseline <br/ ><br>Day 8 <br/ ><br>Day 15
© Copyright 2025. All Rights Reserved by MedPath